For decades, sugar beet for American farmers has been a vital crop, which provides more than half of the country’s home and offers a bumper against volatile markets for corn, soybeans and wheat. However, Reuters states that this year the decline in US sugar consumption in combination with excessive imports has led to surplus. Refined beet sugar prices fell by 33% compared to last year – the lowest since 2019 – with supplies that are expected to remain high in at least 2026.
Experts point to a long-term decline in sugar intake, intensify with inflation and growing popularity of GLP-1 weight loss drugs. Almost 9% of Americans are now taking medicines such as Wegovy and Ozmpemic, according to a study by OC&C consultants, he reported 6% less for AO chocolate 10% less for sweet pastries.
“All consumers suddenly started buying less food in grocery store, so Robert Johansson, a former USDA chief economist and the director of economics and politics for American Sugar Alliance, were listed.
Farmers are struggling with low prices
The decline in demand has been hard to hit by farmers. Michigan CLINT HAGEN grower said, “You have to consume it in moderation as well as anything else. Our product is natural. We’ll let it dictate science.”
Hagen, faces likely loss, delay upgrades of equipment to survive another season. He added: “If you are sick now and tired of sugar beet and you want to find someone to buy these acres far away from you.”
Minnesota farmer Neil Rockstad described the financial tribe: “The consciousness of putting it all the time and working into it and pulling no profit out of it, but hopefully you can stay in business for another season, yeah, it’s frustrating.”
Farmer Idaho Galen Lee also expressed concern: “I think Break-Even would be the best on the beet. And they are usually a crop that helps carry a mortgage for everything else and pay bills.”
Rising costs add pressure
Sugar beet production is expensive and requires specialized equipment, high fertility, fungicides and herbicides. The tariffs for imported chemicals and machines have increased costs. Hagen noted that this summer he needed seven or eight applications of fungicides, from three or four in previous years.
GLP-1 drugs disrupt medical display
In addition to the economic impact, GLP-1 can have unintended consequences for health care. Research presented at the 38th annual congress of the European Nuclear Medicine Association (EANM 2025) shows that these drugs can complicate PET-CT scanning used to detect cancer.
“These drugs change glucose metabolism, stomach motility, and a nice tone that can lead to unique absorption patterns on PET-CT,” Dr. Peter Strouhal, Medical Director of Alliance Medical Ltd. solving this appearing problem. ”
Also read | As the Ozmsian ate the movement plus size
The risks of patients
Incorrect scans interpretations could lead to unnecessary tests, incorrect cancer staging and treatment delay. Dr. Strouhal explained: “Recognition of characteristic gadgets associated with GLP-1 agonists helps avoid unnecessary anxiety and intervention and ensure that patients receive the right care, at the right time, without a detour or doubt.”
Scientists currently do not recommend stopping GLP-1 drugs from PET-CT scanning. Instead, imaging teams should carefully document the history of patient drugs to help interpretation.
Also read | Journey for weight loss Jonah Hill and his way to “physical love” (tagstotranslate) sugar beet
